Skip to main content
SpringerLink
Log in
Book cover

Handbook of Neuroethics pp 1085–1100Cite as

Using Neuropharmaceuticals for Cognitive Enhancement: Policy and Regulatory Issues

  • Reference work entry
  • First Online:

Abstract

This chapter provides an overview of policy and regulatory issues relating to the use of neuropharmaceuticals for cognitive enhancement in normal persons without a cognitive disorder. It draws on experience with a range of policy and regulatory approaches to alcohol, tobacco, pharmaceutical drugs, and illicit drugs and focuses on approaches that target rates of drug use in the population as a whole. The focus on regulatory interventions for the control of neuropharmaceuticals is important because a range of pharmaceutical drugs is often reportedly used and advocated for enhancement purposes. We also examine how more public health interventions such as awareness raising, education, and stigmatization could be used as preventive strategies to reduce the use, and harm associated with the use, of neuropharmaceuticals for cognitive enhancement.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   999.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   999.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Academy of Medical Sciences. (2008). Brain science, addiction and drugs. London: United Kingdom Academy of Medical Sciences.

    Google Scholar 

  • Australian Press Council. (2001). Guideline: Drugs and drug addiction, http://www.presscouncil.org.au/document-search/guideline-drugs-and-drug-addiction/?LocatorGroupID=662&LocatorFormID=677&FromSearch=1. Advisory Guidelines. Accessed 5 Nov 2012.

  • Babor, T., Caulkins, J., Edwards, G., Fischer, B., Foxcroft, D., Humphreys, K., & Strang, J. (2010). Drug policy and the public good. Oxford: Oxford University Press.

    Google Scholar 

  • Bell, S. K., Lucke, J. C., & Hall, W. D. (2012). Lessons for enhancement from the history of cocaine and amphetamine use. AJOB Neuroscience, 3(2), 24–29.

    Article  Google Scholar 

  • Bostrom, N., & Sandberg, A. (2009). Cognitive enhancement: Methods, ethics, regulatory challenges. Science and Engineering Ethics, 15(3), 311–341.

    Article  Google Scholar 

  • British Medical Association. (2007). Boosting your brainpower: Ethical aspects of cognitive enhancements. London: BMA.

    Google Scholar 

  • Carroll, B. C., McLaughlin, T. J., & Blake, D. R. (2006). Patterns and knowledge of nonmedical use of stimulants among college students. Archives of Pediatrics & Adolescent Medicine, 160(5), 481–485.

    Article  Google Scholar 

  • DeSantis, A., Webb, E. M., & Noar, S. M. (2008). Illicit use of prescription ADHD medications on a college campus: A multimethodological approach. Journal of American College Health, 57(3), 315–324.

    Article  Google Scholar 

  • Dubljevic, V. (2012). Toward a legitimate public policy on cognition-enhancement drugs. AJOB Neuroscience, 3(3), 29–33.

    Article  Google Scholar 

  • Fischer, B., Bibby, M., & Bouchard, M. (2010). The global diversion of pharmaceutical drugs non-medical use and diversion of psychotropic prescription drugs in North America: A review of sourcing routes and control measures. Addiction, 105(12), 2062–2070.

    Article  Google Scholar 

  • Forlini, C., & Racine, E. (2009). Autonomy and coercion in academic “cognitive enhancement” using methylphenidate: Perspectives of key stakeholders. Neuroethics, 2(3), 163–177.

    Article  Google Scholar 

  • Forlini, C., & Racine, E. (2012). Added stakeholders, added value(s) to the cognitive enhancement debate: Are academic discourse and professional policies sidestepping values of stakeholders? AJOB Primary Research, 3(1), 33–47.

    Article  Google Scholar 

  • Forlini, C., Gauthier, S., & Racine, E. (2013). Should physicians prescribe cognitive enhancers to healthy individuals? Canadian Medical Association Journal. Online ahead of print: 10.1503/cmaj.121508.

    Google Scholar 

  • Franke, A. G., Bonertz, C., Christmann, M., Huss, M., Fellgiebel, A., Hildt, E., & Lieb, K. (2011). Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry, 44(2), 60–66.

    Article  Google Scholar 

  • Fraser, S., & Moore, D. (2011). Governing through problems: The formulation of policy on amphetamine-type stimulants (ATS) in Australia. The International Journal on Drug Policy, 22(6), 498–506.

    Article  Google Scholar 

  • Government of Quebec. (2009). Psychotropic drugs and expanded uses: An ethical perspective (Position Statement) Quebec: Commission de l’éthique, de la science et de la technologie.

    Google Scholar 

  • Greely, H., Sahakian, B., Harris, J., Kessler, R. C., Gazzaniga, M., Campbell, P., & Farah, M. J. (2008). Towards responsible use of cognitive-enhancing drugs by the healthy. Nature, 456(7223), 702–705.

    Article  Google Scholar 

  • Hall, W. (2004). Feeling ‘better than well:’ Can our experiences with psychoactive drugs help us to meet the challenges of novel neuroenhancement methods? EMBO Reports, 5(12), 1105–1109.

    Article  Google Scholar 

  • Holmes, D. (2012). Prescription drug addiction: The treatment challenge. Lancet, 379(9810), 17–18.

    Article  Google Scholar 

  • Hughes, B., & Winstock, A. R. (2012). Controlling new drugs under marketing regulations. Addiction, 107(11), 1894–1899.

    Article  Google Scholar 

  • Kroutil, L. A., Van Brunt, D. L., Herman-Stahl, M. A., Heller, D. C., Bray, R. M., & Penne, M. A. (2006). Nonmedical use of prescription stimulants in the United States. Drug and Alcohol Dependence, 84(2), 135–143.

    Article  Google Scholar 

  • Larriviere, D., Williams, M. A., Rizzo, M., & Bonnie, R. J. (2009). Responding to requests from adult patients for neuroenhancements: Guidance of the ethics, law and humanities committee. Neurology, 73(17), 1406–1412.

    Article  Google Scholar 

  • Lucke, J. C., Bell, S., Partridge, B., & Hall, W. D. (2011). Deflating the neuroenhancement bubble. AJOB Neuroscience, 2(4), 38–43.

    Article  Google Scholar 

  • Lynch, G., Palmer, L. C., & Gall, C. M. (2011). The likelihood of cognitive enhancement. Pharmacology, Biochemistry, and Behavior, 99(2), 116–129.

    Article  Google Scholar 

  • McCabe, S. E. (2008). Misperceptions of non-medical prescription drug use: A web survey of college students. Addictive Behaviors, 33(5), 713–724.

    Article  Google Scholar 

  • Nielsen, S., & Barratt, M. J. (2009). Prescription drug misuse: Is technology friend or foe? Drug and Alcohol Review, 28(1), 81–86.

    Article  Google Scholar 

  • Orizio, G., Merla, A., Schulz, P. J., & Gelatti, U. (2011). Quality of online pharmacies and websites selling prescription drugs: A systematic review. Journal of Medical Internet Research, 13(3), e74.

    Article  Google Scholar 

  • Outram, S. M., & Racine, E. (2011a). Developing public health approaches to cognitive enhancement: An analysis of current reports. Public Health Ethics, 4(1), 93–105.

    Article  Google Scholar 

  • Outram, S. M., & Racine, E. (2011b). Examining reports and policies on cognitive enhancement: Approaches, rationale, and recommendations. Accountability in Research, 18(5), 323–341.

    Google Scholar 

  • Partridge, B. J., Bell, S. K., Lucke, J. C., Yeates, S., & Hall, W. D. (2011). Smart drugs “as common as coffee”: Media hype about neuroenhancement. PLoS One, 6(11), e28416.

    Article  Google Scholar 

  • Racine, E. (2008). Interdisciplinary approaches for a pragmatic neuroethics. The American Journal of Bioethics, 8(1), 52–53.

    Article  Google Scholar 

  • Racine, E. (2010). Pragmatic neuroethics: Improving treatment and understanding of the mind-brain. Cambridge, MA: The MIT Press.

    Google Scholar 

  • Racine, E., & Forlini, C. (2009). Expectations regarding cognitive enhancement create substantial challenges. Journal of Medical Ethics, 35(8), 469–470.

    Article  Google Scholar 

  • Racine, E., & Forlini, C. (2010). Responding to requests from adult patients for neuroenhancements: Guidance of the ethics, law and humanities committee. [Letter]. Neurology, 74(19), 1555–1556.

    Article  Google Scholar 

  • Repantis, D., Schlattmann, P., Lainsey, O., & Heuser, I. (2008). Antidepressants for neuroenhancement in healthy individuals: A systematic review. Poiesis Prax, 6, 139–174.

    Article  Google Scholar 

  • Repantis, D., Laisney, O., & Heuser, I. (2010a). Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: A systematic review. Pharmacological Research, 61(6), 473–481.

    Article  Google Scholar 

  • Repantis, D., Schlattmann, P., Laisney, O., & Heuser, I. (2010b). Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacological Research, 62(3), 187–206.

    Article  Google Scholar 

  • Roche, A. M., Bywood, P., Pidd, K., Freeman, T., & Steenson, T. (2009). Drug testing in Australian schools: Policy implications and considerations of punitive, deterrence and/or prevention measures. The International Journal on Drug Policy, 20(6), 521–528.

    Article  Google Scholar 

  • Room, R., & Hall, W. (2012). Population approaches to alcohol, tobacco and drugs: Effectiveness, ethics and interplay with addiction neuroscience. In A. Carter, W. D. Hall, & J. Illes (Eds.), Addiction neuroethics (pp. 247–260). London: Academic Press.

    Chapter  Google Scholar 

  • Rosenfield, D., Hebert, P. C., Stanbrook, M. B., Flegel, K., & MacDonald, N. E. (2011). Time to address stimulant abuse on our campuses. [Editorial]. Canadian Medical Association Journal, 183(12), 1345.

    Article  Google Scholar 

  • Sandberg, A., & Savulescu, J. (2011). The social and economic impacts of cognitive enhancement. In J. Savulescu, R. ter Meulen, & G. Kahane (Eds.), Enhancing human capacities. Oxford, UK: Blackwell.

    Google Scholar 

  • Savulescu, J., & Bostrom, N. (Eds.). (2009). Human enhancement. Oxford: Oxford University Press.

    Google Scholar 

  • Smith, M. E., & Farah, M. J. (2011). Are prescription stimulants “smart pills”? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychological Bulletin, 137(5), 717–741. 717.

    Article  Google Scholar 

  • Stone, A. M., & Merlo, L. J. (2011). Attitudes of college students toward mental illness stigma and the misuse of psychiatric medications. The Journal of Clinical Psychiatry, 72(2), 134–139.

    Article  Google Scholar 

  • Strang, J., Babor, T., Caulkins, J., Fischer, B., Foxcroft, D., & Humphreys, K. (2012). Drug policy and the public good: Evidence for effective interventions. The Lancet, 379(9810), 71–83.

    Article  Google Scholar 

  • Swanson, J. M., Wigal, T. L., & Volkow, N. D. (2011). Contrast of medical and nonmedical use of stimulant drugs, basis for the distinction, and risk of addiction: Comment on Smith and Farah. [Comment]. Psychological Bulletin, 137(5), 742–748.

    Article  Google Scholar 

  • Teter, C. J., McCabe, S. E., LaGrange, K., Cranford, J. A., & Boyd, C. J. (2006). Illicit use of specific prescription stimulants among college students: Prevalence, motives, and routes of administration. Pharmacotherapy, 26(10), 1501–1510.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Queensland Centre for Clinical Research, The University of Queensland, Room 709, Building 71/918, Brisbane, QLD, 4029, Australia

    Jayne Lucke & Brad Partridge

  2. Institut de recherches cliniques de Montréal (IRCM), Neuroethics Research Unit, Montréal, QC, Canada

    Cynthia Forlini

  3. Neuroethics Research Unit, Institut de recherches cliniques de Montréal, 110 avenue des Pins Ouest, H2W 1R7, Montréal, QC, Canada

    Eric Racine

  4. Department of Medicine and Department of Social and Preventive Medicine, Université de Montréal, Montréal, QC, Canada

    Cynthia Forlini & Eric Racine

  5. Departments of Neurology and Neurosurgery, Experimental Medicine & Biomedical Ethics Unit, McGill University, Montréal, QC, Canada

    Eric Racine

Authors
  1. Jayne Lucke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brad Partridge
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cynthia Forlini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eric Racine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jayne Lucke .

Editor information

Editors and Affiliations

  1. Institute for Ethics and History of Medicine, University of Tübingen, Tübingen, Germany

    Jens Clausen

  2. The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Australia

    Neil Levy

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media Dordrecht

About this entry

Cite this entry

Lucke, J., Partridge, B., Forlini, C., Racine, E. (2015). Using Neuropharmaceuticals for Cognitive Enhancement: Policy and Regulatory Issues. In: Clausen, J., Levy, N. (eds) Handbook of Neuroethics. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-4707-4_72

Download citation

  • DOI: https://doi.org/10.1007/978-94-007-4707-4_72

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-007-4706-7

  • Online ISBN: 978-94-007-4707-4

  • eBook Packages: Humanities, Social Sciences and Law

Publish with us

Policies and ethics

Search

Navigation